177 related articles for article (PubMed ID: 9130691)
1. Decitabine studies in chronic and acute myelogenous leukemia.
Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
[No Abstract] [Full Text] [Related]
2. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
[TBL] [Abstract][Full Text] [Related]
4. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H
Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582
[No Abstract] [Full Text] [Related]
5. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Kantarjian HM; O'Brien SM; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios MB; de Vos D; Talpaz M
Leukemia; 1997 Oct; 11(10):1617-20. PubMed ID: 9324279
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
[TBL] [Abstract][Full Text] [Related]
7. Decitabine has promising clinical activity in chronic myeloid leukemia.
Expert Rev Anticancer Ther; 2002 Dec; 2(6):620-1. PubMed ID: 12503205
[No Abstract] [Full Text] [Related]
8. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
9. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
Schwartsmann G; Fernandes MS; Schaan MD; Moschen M; Gerhardt LM; Di Leone L; Loitzembauer B; Kalakun L
Leukemia; 1997 Mar; 11 Suppl 1():S28-31. PubMed ID: 9130689
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.
Tong X; Li J; Zhou Z; Zheng D; Liu J; Su C
Leuk Lymphoma; 2015 Jun; 56(6):1911-3. PubMed ID: 25426665
[No Abstract] [Full Text] [Related]
11. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
[No Abstract] [Full Text] [Related]
12. Studies of decitabine with allogeneic progenitor cell transplantation.
Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Issa JP; Gharibyan V; Cortes J; Jelinek J; Morris G; Verstovsek S; Talpaz M; Garcia-Manero G; Kantarjian HM
J Clin Oncol; 2005 Jun; 23(17):3948-56. PubMed ID: 15883410
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L
Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
[TBL] [Abstract][Full Text] [Related]
16. Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
Yogarajah M; Montgomery N; Matson M; Blanchard L; Frank C; Gallagher S; Pepin K; Vaught L; Muluneh B; Foster MC; Zeidner JF
Leuk Lymphoma; 2018 Dec; 59(12):3010-3012. PubMed ID: 29749763
[No Abstract] [Full Text] [Related]
17. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
Singh SN; Cao Q; Gojo I; Rapoport AP; Akpek G
Bone Marrow Transplant; 2012 Jul; 47(7):1008-9. PubMed ID: 22080965
[No Abstract] [Full Text] [Related]
18. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
[TBL] [Abstract][Full Text] [Related]
19. Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine.
Mulay S; Bauer F; Boruchov A; Bilgrami S
Leuk Lymphoma; 2011 Feb; 52(2):341-3. PubMed ID: 21142783
[No Abstract] [Full Text] [Related]
20. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
